Clinical Trial Update: Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating sofosbuvir/velpatasvir with ribavirin in adults with chronic hepatitis C who previously participated in a Gilead HCV study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-07-28